Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The form provides key information about the dealings of the exempt principal trader with Allergy Therapeutics plc. The form states that on November 2, 2023, Panmure Gordon (UK) Limited made purchases and sales of Allergy Therapeutics plc's 0.1p ordinary shares. The form also includes details of the highest and lowest prices per unit paid/received for the securities.
The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options, related to Allergy Therapeutics plc. It also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives.
The disclosure was made on November 3, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969. The form concludes by stating that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.